Skip to main content

Gene Myers, Graham Cameron, Duncan Campbell, Michael Liebman, Jens Finnern, Ralph Humberg, Manfred Voglmaier, Jrgen Klenk

Premium

Gene Myers has joined the scientific advisory board of CuraGen’s genomics technology subsidiary 454 Life Sciences. As VP of informatics at Celera Genomics, Myers led the assembly and analysis of the company’s human genome sequencing project. He is currently a professor of computer science at the University of California, Berkeley.

 

Confirmant has named several new members to is scientific advisory board: Graham Cameron, associate director of the EBI; Duncan Campbell, director of the MRC HGMP Resource Center at the Wellcome Trust Genome Campus; and Michael Liebman, director of computational biology and biomedical informatics at the Abramson Cancer Center of the University of Pennsylvania.

 

Munich, Germany-based bioinformatics firm Definiens has named Jens Finnern as director of business development, Ralph Humberg as director of channel sales, and Manfred Voglmaier as director of sales. The company also promoted J rgen Klenk from director of R&D to VP and CTO. Prior to joining Definiens, Finnern was the executive managing director of the German Cancer Institute, Humberg worked as director of marketing for ADVA Optical Networking, and Voglmaier was managing director of NuGenesis Technologies.

 

Filed under

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.